Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Other Routine +

Delivra Health Brands Enters into Licence Agreement with Peak Processing to Manufacture and Distribute Its Topical Brand LivRelief Infused(TM)

Delivra Secures Manufacturing Partner Amidst Revenue Decline and EBITDA Widenings

By The Northwire Desk — AI Analysis Apr 22, 2026 · 17:45 DHB · 0.14 Delivra Health Brands Inc.
Executive Summary
  • Licensing Agreement: Delivra Health Brands (via subsidiary LivCorp Inc.) entered a five-year license agreement with Peak Processing Solutions (ASX: PKP) to manufacture, distribute, and sell LivRelief Infused topicals in Canada.
  • Renewal Terms: The agreement includes three automatic renewals of three years each following the initial term.
  • Product Scope: Covers CBD-only, 1:1 THC/CBD, and Extra Strength CBD topical creams.
  • Dilution Event: Company granted 440,000 incentive stock options to directors/officers/consultants at $0.14 per share, vesting one-third annually over five years.
  • Strategic Intent: CEO Gord Davey states the partnership strengthens market position and realizes benefits beyond existing channels.
Material Impact
  • Confirmation of Strategy: The news confirms a transition strategy explicitly mentioned in the Q2 FY26 results (Feb 27, 2026), which cited "reduced LivRelief Infused cream sales due to a new licensed distributor." This is not unexpected information but rather the formalization of a known operational shift.
  • Revenue Impact: While securing manufacturing and distribution is positive for long-term stability, it does not immediately reverse the 12% YoY revenue decline reported in Q2 FY26 (C$2.43M). The deal mitigates future risk but does not guarantee immediate top-line growth.
  • Financial Health Context: The news arrives after a period of deteriorating profitability. Adjusted EBITDA widened to $(369)K in Q2 FY26 from positive territory in Q1 FY26 ($56K). This licensing deal addresses supply chain continuity but does not address the margin compression (40% gross profit vs 47% YoY) or negative cash flow.
  • Dilution Risk: The stock option grant at $0.14 aligns with current trading prices, indicating management compensation is tied to recovery, but adds incremental share count pressure in a declining market environment.
DHB · Price
Company Overview
  • Company: Delivra Health Brands Inc. operates wellness brands focused on sleep, pain relief, and topical treatments.
  • Flagship Products: Dream Water (sleep aid beverages) and LivRelief (topical creams).
  • Development Status: LivRelief Infused topicals are currently transitioning to a new manufacturing partner (Peak Processing). Dream Water Kids Gummies are in the US launch phase (June 2026).
  • Market Position: The company relies heavily on e-commerce growth (+26% YoY for Dream Water) but faces headwinds in retail channels (-12% revenue overall).
Read the original news release →

More from Delivra Health Brands Inc.

May 29, 2026 · 17:46

Delivra Health's Overseas Nightmare: Conflict Chokes Revenue 60% and Deepens Losses

Earnings Mar 19, 2026 · 17:31

Delivra Health Brands Launches Dream Water(R) Kids Sleep Gummies in the United States Market

Management Feb 27, 2026 · 18:51

SEDAR Interim Financial Statements

None Feb 27, 2026 · 18:46

Delivra Health and Its Brands LivRelief (TM) and Dream Water (TM) Report Results for Second Quarter of Fiscal 2026

Earnings Nov 10, 2025 · 07:26

Delivra Health Brands Reports Financial Results for First Quarter of Fiscal 2026 Highlighting Continued Growth of Dream Water (R) and LivRelief(TM)

Earnings Oct 06, 2025 · 07:31

Delivra Health Brands Reports Continued Revenue Growth and Positive Adjusted EBITDA(1) in FY2025

Earnings